YungShin Global Holding Corp
TWSE:3705
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
45.55
62.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
YungShin Global Holding Corp
Cost of Revenue
YungShin Global Holding Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cost of Revenue
-NT$4.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cost of Revenue
-NT$2.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cost of Revenue
-NT$2.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Cost of Revenue
-NT$904.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cost of Revenue
-NT$7.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-24%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cost of Revenue
-NT$3.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-8%
|
|
YungShin Global Holding Corp
Glance View
YungShin Global Holding Corp. engages in resources integration and business development. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-01-03. The firm mainly invests in the manufacturing and trading of various medicines, animal medicines, Chinese medicines, health foods, chemicals, cosmetics, soaps, medicated soaps, various detergents, spices, feeds, diagnostic equipment and reagents. The firm also invests in the sales of pharmaceuticals, pharmaceutical raw materials and health food raw materials, as well as the production and sales of chemical drugs and feed additives and other animal products. The main products are antibiotic injection items, various aqueous solutions for medicine and oral tablets of antibiotics, veterinary drug products, medicated feed additives and non-medicated feed additives and others.
See Also
What is YungShin Global Holding Corp's Cost of Revenue?
Cost of Revenue
-4.2B
TWD
Based on the financial report for Jun 30, 2024, YungShin Global Holding Corp's Cost of Revenue amounts to -4.2B TWD.
What is YungShin Global Holding Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
Over the last year, the Cost of Revenue growth was -4%.
You don't have any saved screeners yet
